Eye-drop vaccine containing copolymer 1 for therapeutic immunization
AssigneeYeda Research and Development Co. Ltd.
InventorsMichal Eisenbach-Schwartz, Sharon Bakalash, Valentin Fulga
Life of this patent
Estimating the term…
Abstract
The invention provides an eye-drop vaccine for therapeutic immunization of a mammal comprising Copolymer 1, a Copolymer 1-related peptide, or a Copolymer 1-related polypeptide, for treating neuronal degeneration caused by an injury or disease, disorder or condition in the central nervous system (CNS) or peripheral nervous system (PNS), for preventing or inhibiting neuronal secondary degeneration which may otherwise follow primary injury in the CNS, for promoting nerve regeneration in the CNS or in the PNS after an injury, disease, disorder or condition or for protecting CNS and PNS cells from glutamate toxicity.
Claims14
A method of therapeutic immunization of a glaucoma patient, which comprises topically administering to the eye of the patient an eye-drop vaccine comprising Copolymer 1 in an amount effective to confer systemic neuroprotection by evoking an immune response and thereby to treat glaucoma in said patient.
A method for reducing neuronal degeneration caused by the neurodegenerative effects of a disease, or for reducing secondary neuronal degeneration that follows the primary neuronal degeneration of an injury, in the central nervous system (CNS) or peripheral nervous system (PNS) of an individual in need thereof, which method comprises immunizing the individual in need by topically administering an eye-drop vaccine to the eye of the individual, said vaccine comprising an active agent comprising Copolymer 1, in an amount effective to confer systemic neuroprotection by evoking an immune response and thereby to reduce said neuronal degeneration caused by injury or disease in said individual.
A method of therapeutic immunization comprising immunizing a human individual in need with an eye-drop vaccine, which comprises an active agent comprising Copolymer 1, wherein said immunizing comprises administering said vaccine to the eye of the individual in an amount effective to confer systemic neuroprotection by evoking an immune response and thereby therapeutic immunization of said human individual.
Dependencies are inferred from the claim text.